Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.

Autor:	Mayoral K; Health Services Research Group, Hospital del Mar Research Institute, Barcelona, Spain.; Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine and Public Health, Universitat Autònoma de Barcelona, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.; Co-first authors., Lizano-Barrantes C; Health Services Research Group, Hospital del Mar Research Institute, Barcelona, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmacy, Universidad de Costa Rica, San Jose, Costa Rica.; Co-first authors., Zamora V; Health Services Research Group, Hospital del Mar Research Institute, Barcelona, Spain.; Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine and Public Health, Universitat Autònoma de Barcelona, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain., Pont A; Health Services Research Group, Hospital del Mar Research Institute, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain., Miret C; Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine and Public Health, Universitat Autònoma de Barcelona, Barcelona, Spain.; Preventive Medicine and Public Health Training Unit PSMar-UPF-ASPB, Parc de Salut Mar, Agència de Salut Pública de Barcelona, Pompeu Fabra University, Barcelona, Spain.; Health Services Evaluation and Clinical Epidemiology Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain., Barrufet C; Health Services Evaluation and Clinical Epidemiology Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain., Caballero-Rabasco MA; Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine and Public Health, Universitat Autònoma de Barcelona, Barcelona, Spain.; Paediatric Pulmonology and Allergy Unit, Paediatric Department, Hospital Del Mar, Barcelona, Spain., Praena-Crespo M; Centro de Salud La Candelaria, Servicio Andaluz de Salud, Seville, Spain.; Grupo de Vías Respiratorias de la Asociación Española de Pediatras de Atención Primaria (AEPAP), Madrid, Spain., Bercedo A; Grupo de Vías Respiratorias de la Asociación Española de Pediatras de Atención Primaria (AEPAP), Madrid, Spain.; Centro de Salud Los Castros, Servicio Cántabro de Salud, Cantabria, Spain., Valdesoiro-Navarrete L; Hospital Universitari Parc Taulí, Sabadell, Spain., Guerra MT; Centro de Salud de Jerez Sur, Servicio Andaluz de Salud, Jerez de la Frontera, Spain., Pardo Y; Health Services Research Group, Hospital del Mar Research Institute, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.; Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Martínez Zapata MJ; CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau, Barcelona, Spain., Garin O; Health Services Research Group, Hospital del Mar Research Institute, Barcelona, Spain.; CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Ferrer M; Health Services Research Group, Hospital del Mar Research Institute, Barcelona, Spain mferrer@imim.es.; CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	European respiratory review : an official journal of the European Respiratory Society [Eur Respir Rev] 2023 Oct 18; Vol. 32 (170). Date of Electronic Publication: 2023 Oct 18 (Print Publication: 2023).
DOI:	10.1183/16000617.0124-2023
Abstrakt:	Background: We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo. Methods: Protocol registration CRD42020216098 (www.crd.york.ac.uk/PROSPERO). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model. Results: Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21-689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (-0.12, -0.20- -0.05 and -0.23, -0.41- -0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44-1.36). Conclusions: The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment. Competing Interests: Conflict of interest: All authors have nothing to disclose. (Copyright ©The authors 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu